Fintech PR
New Tech Breakthrough Makes $2.5 Trillion Hydrogen Boom Possible
FN Media Group Presents Oilprice.com Market Commentary
LONDON, Aug. 25, 2023 /PRNewswire/ — The U.S. government has announced a proposed $7 billion (for starters) on desperately needed breakthroughs in clean hydrogen production. The Department of Energy’s (DoE) biggest bet is on nuclear power plants, which they are hoping to convert into North America’s premier clean hydrogen producers. Companies mentioned in this release include: Ballard Power Systems Inc. (NASDAQ: BLDP), Plug Power Inc. (NASDAQ: PLUG), Linde plc (NYSE: LIN), Shell (NYSE: SHEL), BP (NYSE: BP).
Those billions of dollars are being poured into technological innovation, lowering costs and scaling up the production of clean hydrogen, including through the use of nuclear power plants in New York, Ohio, Minnesota and Arizona.
For now, the majority of hydrogen in the United States is produced by natural gas reforming in large central plants—an important step in the energy transition. The end goal, however, is to produce hydrogen without creating carbon emissions, and that’s what the federal government’s $7billion spend is all about.
At four nuclear plants across the country, scientists are trying to perfect a process called ‘electrolysis’ to create pure, clean hydrogen. The process involves splitting water into pure hydrogen and oxygen using high temperature electrolyzers. For now, however, the process is prohibitively expensive and energy intensive.
That could make this recent breakthrough all the more significant …
GH Power has developed a unique renewable energy technology that uses exothermic reactions to create three highly sought-after green outputs: hydrogen, alumina (aluminum oxide) and exothermic heat, killing three birds with one high-tech stone.
The hydrogen produced by the modular version of GH Power’s 2MW reactor is pure and clean, with zero emissions, zero carbon and zero waste, using only 2 inputs (recycled aluminum and water).
GH Power has been developing the new type of reaction for hydrogen production over the past 7 years, and now it’s gearing up to flip the switch on the first commercial reactor of its kind in Hamilton Ontario, Canada.
Flipping the switch on this new reactor comes at a critical juncture in the global energy transition. The Hydrogen Council estimates that hydrogen will represent 18% of all energy delivered to end users by 2050, avoiding 6 gigatonnes of carbon emissions annually and turning around an approximated $2.5 trillion in annual sales (not to mention creating 30 million jobs globally).
VISUALIZING A FUTURE POWERED BY CLEAN HYDROGEN
GH Power’s reactor is self-sustaining, zero emission and is a net producer of energy for consumption. It’s 100% clean and modular, which means it can be assembled on site to power North America’s industries for the first time with clean energy and cost competitive with conventional fossil fuels.
It also produces green hydrogen, exothermic heat, as well as highly valuable green alumina, which has numerous commercial applications used for everything from lithium-ion batteries and LED lighting to semiconductor production.
The GH Power process is proprietary and breakthrough:
GH Power is planning to develop a plant which produces 11,700 Tonnes of green hydrogen per year to fuel 30 MW combined cycle plant with a net output of 27 MW.
For now, the DoE puts the cost of producing hydrogen from renewable energy at about $5 per kilogram, which is about 3X higher than the price of producing hydrogen from natural gas. The DoE’s goal is to see clean hydrogen production costs decline by 80% to $1 per kilogram in a decade.
By the company’s estimates, GH Power’s reactor is already 60% cheaper than producing hydrogen by electrolysis, and it is a net producer of electricity to the grid. Its green alumina co-product production costs are also over 85% cheaper than the most commonly used processes currently used for alumina production that rely on hydrochloric acid leaching and hydrolysis for alumina production. This could be a game changer in the decarbonization of the critical sector.
Finally, GH Power’s base 27MW net output plant design is forecast to produce a carbon offset of 1.2 million tonnes annually (based on displacing a coal fired plant the same size)
The company has also had successful tests using scrap steel (iron) as another metal fuel for hydrogen generation. The use of recycled metals provides a scalable solution with a much lower costs basis at under a $1/kg hydrogen. Scrap iron is the most widely available metal fuel in most markets. Not only is this a cost breakthrough, but it is a proprietary technology that embraces the idea of a circular economy with zero emissions.
The process uses recycled scrap aluminum as the key input. That aluminum is then mixed with water through a proprietary reactor designed to continuously operate to produce hydrogen, alumina and exothermic heat (power) with zero emissions. Scrap or recycled aluminum is widely available in almost every market, and can be found for as little as $1.50/kg.
It’s a new technology that can run full circle from using recyclable materials to help other companies, organizations, and industries to meet their own net-zero commitments. And it’s all modular and brings the energy to within the last mile of the energy user. For hydrogen, it could be a huge competitive advantage to be able to build a plant right where it’s needed, without massive hydrogen storage facilities and without transportation needs.
FLIPPING THE SWITCH ON THE FIRST REACTOR
GH Power and its team of engineers have already completed Phase 1 testing of their 2MW reactor in Hamilton, Ontario, and Phase 2 testing began on June 30th. Next step is to move into commercial operations and 24-hour continuous operations.
Revenue generation is forecast to begin in the fourth quarter, and then the future is all about scaling up from 2MW reactors to a 27MW Net Output power solution.
The scaled-up 27 Net Output MW version of this reactor, planned for the near future, will produce the same three green outputs which can be blended with natural gas in a turbine. This could allow GH Power’s solution to integrate with existing natural gas power plants and allow companies to utilize existing assets while making a serious reduction in CO2 emissions.
The world needs 520 million tonnes of hydrogen to achieve net-zero targets by 2050, according to the International Energy Agency (IEA). Given the current state of advancement with electrolysis for producing hydrogen and the associated costs, we won’t make that goal without alternative breakthroughs such as GH Power’s.
This award-winning technology is the result of seven years of painstaking research by world-class scientists and engineers, led by GH Power CEO Dave White, a veteran engineer in the power generation space. Combined, the GH Power team has, has well over a century of power generation experience in the design, build and operation of power plants, refineries, and other energy infrastructure.
Chief Engineer Ken Stewart has been designing and managing thermal power plant and petrochemical processes for over four decades and across eight different power plants in North Americ, while COO Gary Grahn brings to the table 25 years of international energy experience, including in oil, gas, minerals, metals and utilities.
GH Power has been working closely with Carleton University and is the recipient of a $2.2-million grant from a joint German-Canadian government program as part of Canada’s alliance with Germany to bolster its hydrogen strategy. It’s a feather in Canada’s cap as the country seeks to become a top global supplier of clean hydrogen with a transatlantic supply chain.
The idea itself is in line with what world-renowned physicist Neil de Grasse Tyson calls the ‘cosmic perspective.’ Large-scale green hydrogen projects in existence today are only as clean as the energy required to produce them and only as plausible as the cost required to get to the end game. “The only practical solution for society to reduce carbon emissions is to transition from 100% fossil fuels to cleaner tech, and one of the steps in tackling this is to blend cost competitive green hydrogen with fossil fuels and ramp up the hydrogen content whenever possible,” noted Dave White, GH Power CEO.
Hydrogen Is Everywhere
Ballard Power Systems Inc. (NASDAQ:BLDP) has firmly established its presence in the vanguard of the fuel cell revolution. Their pioneering proton exchange membrane (PEM) technology is powering various transportation sectors, ranging from buses to trains. This makes Ballard not just a producer, but an influencer, guiding the green transit narrative globally.
The broader vision of Ballard is shaping the industry’s future trajectory. Investors looking to align with a forward-looking company would find Ballard’s approach and ethos resonating with global sustainability goals.
Plug Power Inc. (NASDAQ:PLUG) innovative hydrogen fuel cell systems are carving a new path in the green energy sector. Their solutions, aimed at replacing conventional batteries, mark a transformative shift in energy storage and application.
The commitment Plug Power demonstrates toward a sustainable energy future makes it a critical player in the hydrogen space. As industries transition, investors can anticipate a rising demand for Plug Power’s trailblazing solutions.
Linde plc (NYSE:LIN), with its extensive history in the industrial gas domain, is making commendable strides in the hydrogen space. Their approach is holistic, focusing on every aspect from production to infrastructure, underscoring a commitment that feels both deep and genuine.
Linde offers stability and innovation in equal measure for investors. Their vast experience combined with a proactive approach to the hydrogen revolution paints a picture of steady growth and visionary leadership.
Shell’s (NYSE:SHEL) transition narrative is both fascinating and instructive. Moving from a traditional oil major to a diversified energy company, their hydrogen initiatives reflect a broader shift towards sustainability and innovation.
Their projects in the hydrogen domain, from refueling stations to research collaborations, indicate a comprehensive and future-ready strategy. Shell’s pivot towards hydrogen is not an afterthought; it’s an integral part of their future roadmap.
BP’s (NYSE:BP) rebranding from ‘British Petroleum’ to ‘Beyond Petroleum’ is symbolic of its evolution. Once a stalwart of the traditional energy sector, it’s now championing the green energy revolution, with hydrogen being a key focus.
Their endeavors in hydrogen, be it through investments or partnerships, showcase a progressive mindset. By positioning hydrogen as a cornerstone of their future growth strategy, they’re aligning with global sustainability goals.
By. James Stafford
**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**
Forward-Looking Statements
This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include that the US government is funding development of hydrogen technologies; that billions of dollars are being invested in clean hydrogen producers; that governments are aiming to help develop carbon-free clean hydrogen solutions; that nuclear power plants are being utilized to perfect electrolysis for creation of pure, clean hydrogen; that hydrogen power will be utilized as a main source of energy for the global economy in the future and replace fossil fuels and other competing alternative technologies in the future; that GH Power Inc.’s technology will be developed, commercially implemented and achieve widespread market acceptance; that GH Power will complete the development of a hydrogen reactor that will produce hydrogen 60% cheaper than by electrolysis, become a net producer of energy to the supply grid, co-produce alumina which is 85% cheaper than current production methods; that GH Power’s technology will be revolutionary in the decarbonization of the energy sector; that GH Power’s small pilot model will be scalable at the commercial level in the proposed reactor in Hamilton, Ontario, and will achieve the anticipated results of clean, carbon-free energy production and related bi-products; that GH Power can finance ongoing operations and development; that GH Power can achieve its business plans and objectives as anticipated. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Risks that could change or prevent these statements from coming to fruition including that government may fund the development of alternative technologies instead of hydrogen based technologies; that hydrogen technology may fail to gain commercial acceptance due to safety, cost or other issues; that alternative technologies are preferred in the future to hydrogen technologies as the main replacement of fossil fuels and other energy sources; that GH Power Inc.’s technology may fail to be completely or successfully developed and commercially implemented; that alternative technologies may gain wider acceptance than those of GH Power for various reasons; that alternative technologies may result in greater energy savings and necessary bi-products; that GH Power’s technology may fail to deliver the results anticipated in a commercial setting; that GH Power’s reactor may not be developed as anticipated or at all; that GH Power may be unable to finance its ongoing operations and development; that the business of GH Power may be unsuccessful for various reasons. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
DISCLAIMERS
This communication is for entertainment purposes only. Never invest purely based on our communication. We have not been compensated by GH Power Inc. for this article but may in the future be compensated to conduct investor awareness advertising and marketing for GH Power Inc. The information in our communications and on our website has not been independently verified and is not guaranteed to be correct. The content of this article is based solely on our opinions which are based on very limited analysis and we are not professional analysts or advisors.
SHARE OWNERSHIP. The owner of Oilprice.com owns shares of GH Power Inc. and therefore has an incentive to see the featured company perform well if its securities becomes listed on a stock exchange. If the securities of GH Power become listed on a stock exchange, the owner of Oilprice.com will not notify the market when it decides to buy more or sell shares of GH Power Inc. in the market. The owner of Oilprice.com will be buying and selling shares of this issuer for its own profit. This is why we are biased in our views and opinions in this article and why we stress that you should conduct your own extensive due diligence regarding the Company as well as seek the advice of your professional financial advisor or a registered broker-dealer before you consider investing in any securities of the company or otherwise.
NOT AN INVESTMENT ADVISOR. Oilprice.com is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation.
ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making any investment. This communication should not be used as a basis for making any investment in any securities.
RISK OF INVESTING. Investing is inherently risky. Don’t invest or trade with money you can’t afford to lose. This is neither a solicitation nor an offer to invest or buy/sell securities. No representation is being made that any stock investment, acquisition or disposition will or is likely to achieve profits.
DISCLAIMER: OilPrice.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with OilPrice.com or any company mentioned herein. The commentary, views and opinions expressed in this release by OilPrice.com are solely those of OilPrice.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact e-mail: [email protected] U.S. Phone: +1(954)345-0611
View original content:https://www.prnewswire.co.uk/news-releases/new-tech-breakthrough-makes-2-5-trillion-hydrogen-boom-possible-301909878.html
Fintech PR
The Office of the Executive Committee of the WMC Released the List of “Top 500 Chinese Manufacturing Enterprises in 2023”
HEFEI, China, Sept. 22, 2023 /PRNewswire/ — The 2023 World Manufacturing Convention (WMC) was opened on September 20 in Hefei, Anhui Province, China. In the convention, the list of “Top 500 Chinese Manufacturing Enterprises in 2023” was released, indicating that the operating revenue of China’s top 500 manufacturing enterprises in 2023 has exceeded 50 trillion RMB for the first time, reaching 51.06 trillion RMB, which was an increase of 8.38%.
Among the top 500 manufacturing enterprises, the heavy chemical industry still occupies the main position, and four out of the five industries with the largest operating revenue belong to the heavy chemical industries. Meanwhile, the pace of development of strategic emerging industries has accelerated, and most of the enterprises with the top operating revenue and net profit growth are strategic emerging industry enterprises. The top five industry’s average revenue growth rates are from power batteries and energy storage batteries, wind energy, solar equipment manufacturing, medical equipment manufacturing, computer and office equipment and chemical fiber manufacturing, of which the top three growth rate reached more than 45%, respectively 59.72%, 49.42%, 45.54%. According to the analysis of the ranking, the total R&D expenses of China’s top 500 manufacturing enterprises in 2023 have reached 109.6215 billion RMB, which was an increase of 3.83% over the previous year; the R&D intensity was 2.33%, which is at a high level in recent years. The average R&D expenses of industries such as aerospace, communication equipment manufacturing, railway traffic equipment manufacturing, textile printing and dyeing are at the forefront from the perspective of various industries.
The “2023 Development Report on Anhui Manufacturing” prepared by the Anhui Provincial Department of Economy and Information Technology was also released on the day of the convention. The report shows that the average annual growth rate of industrial value added of enterprises above the designated size in Anhui Province was 9.5% from 2012 to 2022, ranking the first in the central region, the first in the Yangtze River Delta and the fourth in whole China. In 2022, the province’s industrial enterprises above the designated size have achieved an operating revenue of 4.9 trillion RMB, ranking 10th in the country. Among them, manufacturing enterprises above the designated size have achieved an operating revenue of 4.4 trillion RMB; the added value of the manufacturing industry has exceeded 1 trillion RMB, accounting for 26.5% of GDP, which was an increase of 0.3 percentage points over the previous year.
In recent years, Anhui’s manufacturing industry has accelerated the development of integrated clustering, especially the clustering of advanced manufacturing chains, forming an unformidable trend. The top one industry is “automobile” with irresistible force, while the PV and energy storage gathering “sparkling light” into a raging torch, the IC industry showing its brilliant “core”, the new “displays and screens” experiencing a rapid boom, and the AI “valley” astonishing the world. A number of industrial landmarks have become an important force leading the trend of China’s and even the world’s manufacturing industry.
Contact: Yuan Fan
Tel: 0086- 13552640063
E-mail: [email protected]
Photo – https://mma.prnewswire.com/media/2218768/World_Manufacturing_Convention.jpg
Logo – https://mma.prnewswire.com/media/2218767/World_Manufacturing_Convention_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/the-office-of-the-executive-committee-of-the-wmc-released-the-list-of-top-500-chinese-manufacturing-enterprises-in-2023-301936299.html
Fintech PR
Asian International Arbitration Centre and SOAS University of London, Arbitration and Dispute Resolution Centre sign MoU to promote best practice in arbitration
LONDON, Sept. 22, 2023 /PRNewswire/ — The Asian International Arbitration Centre (AIAC), Kuala Lumpur, and SOAS University of London, Arbitration and Dispute Resolution Centre (SADRC) have yesterday (Thursday 21 September) signed a Memorandum of Understanding to advance collaboration and promote best practice in alternative dispute resolution techniques, including arbitration.
The MoU will see the AIAC and SADRC further develop teaching and research activities in alternative dispute resolution in line with international best practice, to coordinate efforts to promote the use of alternative dispute resolution.
Azalina Othman Said, Malaysia’s Minister of Law and Institutional Reform, was in London to attend the MoU signing, and offer it Malaysia’s full support to increase dialogue in arbitration. The Minister attend the MoU signing alongside Malaysia’s High Commissioner to the UK Dato’ Zakri Jaafar, Solicitor General II of the Attorney General’s Chambers of Malaysia, Datuk Almalena Sharmila binti Dato’ Dr. Johan, and Deputy Director General of the Legal Affairs Division of the Prime Minister’s Department, Dr. Punitha Silivarajoo. The Head of Legal Services Trade and Promotion at the UK Ministry of Justice, Holly O’Callaghan, attended to offer the UK Government’s support.
Speaking about the MoU signing, Emilia Onyema, Professor of International Commercial law, SOAS & Director, SADRC, said:
“At the SADRC, we are proud that today we have become a partner of the Asian International Arbitration Centre. Through signing this MoU, we hope to promote alternative dispute resolution techniques in our SOAS regions, Asia, Middle East and Africa, and particularly Malaysia, and learn from our shared experiences.”
Sundra Rajoo, Director of AIAC, said:
“We are delighted that today, the Asian International Arbitration Centre has formally agreed a MoU with SOAS University of London’s prestigious new Arbitration and Dispute Resolution Centre. The formalization of the MoU between both institutions is indeed a remarkable and significant achievement. We firmly believe that through this innovative partnership, we can enhance our joint efforts to promote best practices in alternative dispute resolution, benefiting not only the UK and Malaysia but also the broader Asian and African region.”
Azalina Othman Said, Malaysia’s Minister of Law and Institutional Reform, said:
”The UK and Malaysia have a long shared history of collaborating to tackle mutual challenges, and the signing of the MoU between the Asian International Arbitration Centre and SOAS University of London’s Arbitration and Dispute Resolution Centre underscores the depth of our relationship and our commitment to advancing global best practices in arbitration.”
In practical terms, this collaboration would include steps to encourage, enhance and promote the following areas of cooperation:
- Joint courses and training;
- Joint research programmes;
- Contribution of expertise – such as researchers, panellists, speakers and guest lecturers – to initiatives which share common goals;
- Publication of academic journals, books and newsletters;
- Student internship programmes;
- Organising or hosting joint conferences, workshops, seminars and forums.
In addition to arbitration, the two centres have committed to also promote Islamic arbitration, sports arbitration, mediation, adjudication, and domain name dispute resolution as alternative dispute resolution methods.
The MoU signing comes ahead of the inaugural London International Arbitration Colloquium, which will take place on Monday 25 September at the International Dispute Resolution Centre in London, to consider the role of international arbitration involving sovereign states.
Over the course of three panel sessions, guests will hear expert insights on jurisdictional challenges in investment arbitration, the impact of investment claims on states and their sovereignty, and the role of third-party funding in access to justice.
Contact
For more information, contact:
- AIAC communication team via [email protected]
- SADRC via [email protected]
Fintech PR
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
FN Media Group Presents USA News Group News Commentary
VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ — USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious “Cancer Moonshot” initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.
At the 2023 ASCO Annual Meeting Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) shared exciting results from its important study, called BRACELET-1, with results that caught the eye of RBC Capital. The oral presentation shared at the event described how they’ve been testing a treatment for advanced breast cancer, and it’s looking very promising.
The treatment combines Oncolytics’ flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel. Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed. The results of BRACELET-1 showed that this mixture could slow down the cancer significantly. It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.
For people battling cancer, this means more quality time before the cancer might get worse. Specifically, people getting the combined treatment had about 9.5 good months before the disease advanced, compared to just 6.3 months with only paclitaxel.
Moreover, the new treatment was better at shrinking or even eliminating the cancer. An impressive 37.5% of patients responded to the combined treatment, as opposed to just 13.3% with paclitaxel alone.
“BRACELET-1’s positive results complement prior phase 2 data showing a statistically significant increase in overall survival when pelareorep was combined with paclitaxel by demonstrating similar robust improvements in PFS and ORR in less heavily pre-treated patients,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “Given this exciting finding, our next step is to discuss our data with the FDA to investigate incorporating dual PFS and OS endpoints into our breast cancer program’s registrational study. Including a PFS endpoint will substantially reduce the time to a pivotal readout from the registrational trial, thereby accelerating pelareorep’s path to potential approval as we work to address the urgent needs of HR+/HER2- breast cancer patients.”
Following these encouraging results, Oncolytics Biotech is now ready to take the next steps in advancing its breast cancer program. They’re planning to talk to the FDA and push forward with more registrational studies, having already received Fast Track Designation for pelareorep in the treatment of advanced/metastatic pancreatic cancer, in late 2022. This could make pelareorep an approved treatment for breast cancer sooner than expected.
Another highlight from the ASCO presentations was that of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Zymeworks Inc. (NASDAQ: ZYME). Together the two companies presented promising data from a pivotal Phase 2b trial, evaluating the bispecific antibody, zanidatamab, in HER2-amplified biliary tract cancers (BTC), a particularly aggressive group of cancers that currently lack HER2-targeted treatment options.
The results were not only presented at ASCO but also concurrently published in The Lancet Oncology. They demonstrated meaningful clinical benefit, including antitumor activity, a confirmed objective response rate (cORR) of 41.3%, a median duration of response (DOR) of 12.9 months, and a median progression-free survival (PFS) of 5.5 months.
“The HERIZON-BTC-01 trial advances an exciting field of oncology research where we can leverage next-generation sequencing on BTC patients to understand genomic markers of the disease and choose the appropriate targeted therapies for these patients,” said Shubham Pant, M.D., professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
The data clearly outshines current chemotherapy treatments for BTC, which offer only a 5 to 15 percent ORR and median PFS of 1.4 to 4 months. The Zymeworks-Jazz partnership showcased an oral presentation on the pivotal HERIZON-BTC-01 study results demonstrating zanidatamab’s meaningful clinical benefit and tolerable safety profile in patients with HER2-amplified BTC.
Zanidatamab has already been granted Breakthrough Therapy designation and two Fast Track designations by the FDA, making it an exciting contender in the fight against these tough-to-treat cancers. These exciting results suggest a potential future where targeted treatments like zanidatamab transform the lives of patients in critical need.
With three oral presentations and two poster discussions, and over 25 abstracts, Amgen’s (NASDAQ: AMGN) presence at ASCO included new scientific and clinical research across its diverse oncology portfolio and pipeline, featuring data in hard-to-treat tumor types like non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and small cell lung cancer (SCLC).
“Our presentations at ASCO… illustrate how we’re advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “We’re focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer.”
Highlights from Amgen’s presentations included data on LUMAKRAS® (sotorasib) from the first study evaluating its intracranial efficacy as a KRAS G12C inhibitor versus docetaxel in treated KRAS G12C-mutated advanced NSCLC. Additional analyses from DeLLphi-300 highlighted the safety and clinical efficacy of Tarlatamab, an investigational first-in-class BiTE® immunotherapy, in patients with SCLC with treated and stable brain metastases. Other studies presented novel combinations showing encouraging safety and efficacy in pre-treated KRAS G12C-mutated metastatic CRC and first-line NSCLC.
These presentations showed advances in several therapeutic areas, including hematologic malignancies, melanoma/skin cancers, and gastrointestinal cancers. Some of the key clinical studies presented include the IKEMA study for KYPROLIS®, the PARADIGM trial for VECTIBIX®, and a phase 2 study on IMLYGIC® in advanced sarcoma.
One company also potentially (yet indirectly) making significant strides in the oncology sector is Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a Newark, California-based biopharmaceutical firm. Although not traditionally labeled as a cancer biotech firm, their innovative approach towards blood disorders, notably Polycythemia Vera, a slow-growing blood cancer, underscores their contribution to the broader oncology landscape.
Protagonist’s leading drug candidate, rusfertide (PTG-300), is currently under the microscope. The company recently announced that additional data from the REVIVE study of rusfertide in polycythemia vera would be presented at the annual Congress of the European Hematology Association (EHA). This study holds immense promise as it explores the ability of rusfertide to improve symptoms related to this blood disorder.
The Moffitt Cancer Center and the Department of Malignant Hematology have taken a keen interest in this study, suggesting rusfertide’s potential broader application in the field of hematology and possibly in other forms of cancer. An assistant member of the Department, Dr. Andrew Kuykendall, will present the study results, further demonstrating the deep links between Protagonist’s work and oncology professionals.
Moreover, Protagonist is also advancing their peptide-based new chemical entity, JNJ-2113 (formerly PN-235), which recently showed positive topline results in treating moderate-to-severe plaque psoriasis. While psoriasis is not a form of cancer, the advancement of these biological drugs signals a new direction in treating various human conditions, including cancers.
Article Source: https://usanewsgroup.com/2023/05/31/could-this-company-be-on-track-to-cure-pancreatic-and-breast-cancer-2/
Article Source:
USA News Group
http://USAnewsgroup.com
[email protected]
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
[email protected]
U.S. Phone: +1(954)345-0611
View original content:https://www.prnewswire.co.uk/news-releases/revolutionary-cancer-treatment-advances-promise-brighter-future-amid-federal-funding-uncertainty-301936242.html
-
Fintech1 week agoPraxis Tech posts record growth of 23% in approved transactions in August with its payment orchestration solution
-
Fintech2 weeks agoPan Finance Announces the Q3 Award Winners of 2023
-
Fintech PR1 week agoLyvia Group acquires Arc Consulting, strengthening their position in the Polish tech- and ERP sector
-
Fintech1 week agoBroadridge Announces International Launch of its Next-Gen Digital Investor Communications Platform
-
Fintech1 week agoMastercard and Paysend expand global partnership to enhance cross-border payments for SMEs
-
Fintech PR1 week agoSeadrill Limited Initiates Previously Announced Share Repurchase Program
-
Fintech1 week agoFusionIQ Expands into Canada With All-In-One Platform for Digital Wealth Management
-
Fintech PR1 week agoKick-off to Innovation: Ingenico and AVEM score big by equipping French Stadiums